Intracranial Bleeding in Deep Brain Stimulation Surgery: A Systematic Review and Meta-Analysis

Abstract

<b><i>Background:</i></b> Deep brain stimulation (DBS) is a neurosurgical treatment used for the treatment of movement disorders. Surgical and perioperative complications, although infrequent, can result in clinically significant neurological impairment. <b><i>Objectives:</i></b> In this study, we evaluated the incidence and risk factors of intracranial bleeding in DBS surgery. <b><i>Method:</i></b> Medline, EMBASE, and Cochrane were screened in line with PRISMA 2020 guidelines to capture studies reporting on the incidence of hemorrhagic events in DBS. After removing duplicates, the search yielded 1,510 papers. Abstracts were evaluated by two independent reviewers for relevance. A total of 386 abstracts progressed to the full-text screen and were assessed against eligibility criteria. A total of 151 studies met the criteria and were included in the analysis. Any disagreement between the reviewers was resolved by consensus. Relevant data points were extracted and analyzed in OpenMeta [Analyst] software. <b><i>Results:</i></b> The incidence of intracranial bleeding was 2.5% (95% CI: 2.2–2.8%) per each patient and 1.4% (95% CI: 1.2–1.6%) per each implanted lead. There was no statistically significant difference across implantation targets and clinical indications. Patients who developed an intracranial bleed were on average 5 years older (95% CI: 1.26–13.19), but no difference was observed between the genders (<i>p</i> = 0.891). A nonsignificant trend was observed for a higher risk of bleeding in patients with hypertension (OR: 2.99, 95% CI: 0.97–9.19) (<i>p</i> = 0.056). The use of microelectrode recording did not affect the rate of bleeding (<i>p</i> = 0.79). <b><i>Conclusions:</i></b> In this review, we find that the rate of bleeding per each implanted lead was 1.4% and that older patients had a higher risk of hemorrhage.